Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Investing Activities (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Cash from Investing Activities for 14 consecutive years, with -$47.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 168.64% year-over-year to -$47.3 million, compared with a TTM value of -$75.9 million through Dec 2025, down 154.08%, and an annual FY2025 reading of $40.3 million, down 30.72% over the prior year.
  • Cash from Investing Activities was -$47.3 million for Q4 2025 at Enanta Pharmaceuticals, down from $2.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $72.7 million in Q3 2021 and bottomed at -$145.7 million in Q2 2023.
  • Average Cash from Investing Activities over 5 years is $5.4 million, with a median of $14.0 million recorded in 2022.
  • The sharpest move saw Cash from Investing Activities skyrocketed 2802.68% in 2021, then plummeted 998.57% in 2023.
  • Year by year, Cash from Investing Activities stood at $45.5 million in 2021, then dropped by 26.22% to $33.6 million in 2022, then tumbled by 139.07% to -$13.1 million in 2023, then surged by 625.3% to $68.9 million in 2024, then crashed by 168.64% to -$47.3 million in 2025.
  • Business Quant data shows Cash from Investing Activities for ENTA at -$47.3 million in Q4 2025, $2.3 million in Q3 2025, and -$26.5 million in Q2 2025.